

ASX RELEASE

Investor Trading Update

Wellington, NZ, 18 December 2017: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving the quality of screening, is pleased to provide a trading update for the period to date ended 15 December 2017.

The VHT investor presentation has been updated to reflect sales to 15 Dec 2017 (Q3FY18):

- Annual Recurring Revenue (ARR) is now at NZ\$2.6M, 138% growth on the previous year. We are well on track to meet and exceed our 200% target for the full year.
- Total Contract Value (TCV) signed during Q3 now stands at NZ\$2.4M, 5% above the total for Q2, with two of our traditionally busiest weeks to go, and 115% up compared to Q3FY17 (NZ\$1.1M).
- 35 VolparaEnterprise™ deals have now been signed, covering 2.5% of US women screened.

Notable other recent highlights:

- The first sites to sign one-year VolparaEnterprise™ deals are renewing.
- Memorial Sloan Kettering in New York, one of the world's leading breast cancer centres, has signed a commercial agreement for VolparaEnterprise™.
- VHT has completed its first sales in Japan, following receipt of regulatory clearance in November.

"These figures demonstrate that this has been a great quarter, and we still have two strong weeks of US sales activity ahead," said Dr Ralph Highnam, CEO of Volpara Health Technologies.

"This quarter we have grown sales and seen increased deal flow, while keeping costs flat compared to last year, proving that we have a scalable, sticky product that is being well received in the US market, where we have first-mover advantages.

"We have a very strong sales pipeline, with the interest generated at RSNA, our biggest annual trade show, now translating into qualified leads. With the March quarter, historically our strongest quarter, still ahead of us, we are well on track to exceed our goals for the financial year."

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, and based in Wellington, New Zealand, VHT facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on automated, objective measurements of breast density.

VHT has numerous patents, trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@we-buchan.com
t: +61 3 9866 4722